Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The most commonly reported adverse events with the AZD1222 COVID-19 vaccine are headache and fatigue, a large-scale active ...

A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...

By Sandra Agyeiwaa OTOO Trust Specialists Hospital, in partnership with AstraZeneca, has marked World Asthma Day 2025 with a ...

"MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD" was originally created and published by Pharmaceutical ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to researchers. In a trial where cancers were treated with chemotherapy ...